With expansion a prime focus for businesses worldwide, many
are looking towards rapidly establishing new regions of
The latest business developments from across Europe & Middle East by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
growth, particularly in Europe and the Middle East.
Consortium aims to advance CRC screening
A collaboration aimed at enhancing colorectal cancer (CRC) screening methods is using Surfi x Diagnostics’ photonic diagnostic platform and biomarkers to target molecularly-defi ned high risk precursor lesions and cancer discovered by the Netherlands Cancer Institute (NKI).
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality. While current screening initiatives employ the Fecal Immunochemical Test (FIT) to identify blood in stool samples through hemoglobin detection, approximately 25-30% of cancers and 70% of advanced adenomas go undetected, underscoring the need for more refi ned screening methods
The PHOBICCS project, supported by a PPP grant from the TKI- program Life Sciences & Health of Health~Holland, is centred on the multitargetFIT test [1], developed by researchers at NKI in partnership with NKI spin-off CRCbioscreen and aimed at the detection of three protein biomarkers with a specifi c molecular profi le that makes them prone to progress to cancer.
Jos Lunenberg, CEO of Surfi x Diagnostics, said: “In this project, we will contribute with our innovative photonic diagnostics platform and that fi lls us with pride and promises to become a great showcase of the power of our platform in early cancer detection.”
Dr Beatriz Carvalho from the NKI’s Department of Pathology commented: “With our collective expertise, innovative drive and technological capabilities, we are on track to develop a new screening method that can be further validated through the use of clinical samples available at our institute.”
Dr Henri Theunissen, CEO of CRCbioscreen, added: “We are thrilled to contribute to this consortium. This project aligns with our mission to enhance CRC patient outcomes, bringing our biomarkers one step closer to making a life-saving difference.”
More information online:
ilmt.co/PL/dnRX 1. Presented in Lancet Oncology.
63243pr@reply-direct.com CGT facility receives UK regulatory approval
The Manufacturing and Import Authorisation for Investigational Medicinal Products (MIA(IMP) was awarded following a two-year project resulting in a fl exible and scalable manufacturing hub, with integrated process development and analytical labs, four GMP clean rooms and fi ll/fi nish capability.
The Cell & Gene Therapy Centre designed in-house by eXmoor, is also a zero-carbon facility relying entirely on solar technology and heat pumps.
“This marks the beginning of a new era of growth for eXmoor pharma, now offering a complete set of development, manufacturing and expert consulting services that support cell and gene therapy developers from research to the market,” said CEO Angela Osborne. “As we develop new partnerships, we will expand GMP operations to pivotal and commercial scale within the facility that is designed to increase cleanroom capacity quickly and easily – but we will retain the same underlying commitment to collaboration and focus on achieving our client’s goals.”
eXmoors Bristol facility
Bristol, UK-based cell and gene therapy (CGT) manufacturing partner, eXmoor Pharma has been granted a licence from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), authorising the manufacture of good manufacturing practice (GMP)-grade cell and gene therapy materials for use in clinical trials.
“The Cell & Gene Therapy Centre– one of the largest of its kind in the UK – is ready to manufacture immediately, with GMP and quality teams in place and high customer demand for our capacity over the next 18 months,” added Chief Technology Offi cer Lucy Foley. “We are excited to begin manufacturing and helping new and existing clients to accelerate their products to patients faster.”
More information online:
ilmt.co/PL/xwVq 63247pr@reply-direct.com
Business
Opportunities Europe & Middle East
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96
